表紙
市場調查報告書

蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13):開發中產品分析

Protein Kinase C Epsilon Type - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 363123
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13):開發中產品分析 Protein Kinase C Epsilon Type - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 58 Pages
簡介

本報告提供全球各國的蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13) 治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品的一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 蛋白激酶C-ε (nPKC-ε/EC 2.7.11.13)的概要
  • 治療藥的開發
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Hadasit Medical Research Services & Development Ltd
    • VM Discovery, Inc.
  • 藥物簡介
    • Bryostatin-1
    • DHACP-6
    • 缺血性發作的εPKC活性化用小分子
    • 外傷性腦功能障礙的εPKC活性化用小分子
    • 神經症的εPKC活性化用小分子
    • 第二型糖尿病、胰島素抗性的蛋白激酶C抑制用合成肽
    • VMD-1201
    • VMD-2202
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2412TDB

Summary:

According to the recently published report 'Protein Kinase C Epsilon Type - Pipeline Review, H1 2020'; Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.

The report 'Protein Kinase C Epsilon Type - Pipeline Review, H1 2020' outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 8 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Alzheimer's Disease, Traumatic Brain Injury, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alcohol Addiction, Depression, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Ischemic Stroke, Multiple Sclerosis, Neurology, Parkinson's Disease, Rett Syndrome and Stroke.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
  • The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
    • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
  • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
    • BryoLogyx Inc
    • CHS Pharma Inc
    • Neurotrope Bioscience Inc
    • VM Discovery Inc
    • Young Therapeutics LLC
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
    • Bryostatin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate PKC Epsilon for Neurology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by BryoLogyx Inc, H1 2020
  • Pipeline by CHS Pharma Inc, H1 2020
  • Pipeline by Neurotrope Bioscience Inc, H1 2020
  • Pipeline by VM Discovery Inc, H1 2020
  • Pipeline by Young Therapeutics LLC, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020